Konstantin Voronin1, Patrick Randall, Hugh Myrick, Raymond Anton. 1. Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA. voronin@musc.edu
Abstract
INTRODUCTION: There has been increasing interest in the use of medications that affect the dopamine receptor in the treatment of alcoholism. Aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas. As such, it might act to dampen alcohol reinforcement and craving and/or alter control over alcohol use. The current clinical laboratory study was conducted to evaluate the safety and efficacy of aripiprazole as a potential agent to alter drinking and objective effects of alcohol. METHODS:Thirty nontreatment seeking alcoholics were enrolled in a subacute human laboratory study and received double-blind treatment with up to 15 mg of aripiprazole (n = 15) or identical placebo (n = 15) for 8 days. Tolerability and utility of aripiprazole was monitored during natural drinking over the first 6 days of medication treatment and also during a free choice limited access alcohol consumption paradigm following an initial drink of alcohol in a bar-lab setting on Day 8. RESULTS:Aripiprazole was well tolerated and reduced drinking in nontreatment seeking alcoholics over 6 days of natural drinking--especially in those with lower self control (more impulsive). It also reduced drinks in the bar-lab after a priming drink and broke the link between priming drink induced stimulation and further drinking. During the bar-lab drinking session, there were no differences in subjective high, intoxication, or craving between subjects treated with aripiprazole or placebo. DISCUSSION: This study joins several others in demonstrating the utility of subacute dosing laboratory paradigms for evaluating medication effects in alcoholics. Aripiprazole was well tolerated and lowered alcohol use, especially in those with lower impulse control. Further study is needed to determine the safety and utility of aripiprazole in the treatment of alcoholism and if subgroups of alcoholics are more likely to respond.
RCT Entities:
INTRODUCTION: There has been increasing interest in the use of medications that affect the dopamine receptor in the treatment of alcoholism. Aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas. As such, it might act to dampen alcohol reinforcement and craving and/or alter control over alcohol use. The current clinical laboratory study was conducted to evaluate the safety and efficacy of aripiprazole as a potential agent to alter drinking and objective effects of alcohol. METHODS: Thirty nontreatment seeking alcoholics were enrolled in a subacute human laboratory study and received double-blind treatment with up to 15 mg of aripiprazole (n = 15) or identical placebo (n = 15) for 8 days. Tolerability and utility of aripiprazole was monitored during natural drinking over the first 6 days of medication treatment and also during a free choice limited access alcohol consumption paradigm following an initial drink of alcohol in a bar-lab setting on Day 8. RESULTS:Aripiprazole was well tolerated and reduced drinking in nontreatment seeking alcoholics over 6 days of natural drinking--especially in those with lower self control (more impulsive). It also reduced drinks in the bar-lab after a priming drink and broke the link between priming drink induced stimulation and further drinking. During the bar-lab drinking session, there were no differences in subjective high, intoxication, or craving between subjects treated with aripiprazole or placebo. DISCUSSION: This study joins several others in demonstrating the utility of subacute dosing laboratory paradigms for evaluating medication effects in alcoholics. Aripiprazole was well tolerated and lowered alcohol use, especially in those with lower impulse control. Further study is needed to determine the safety and utility of aripiprazole in the treatment of alcoholism and if subgroups of alcoholics are more likely to respond.
Authors: Christos Pantelis; Murat Yücel; Stephen J Wood; Dennis Velakoulis; Daqiang Sun; Gregor Berger; Geoff W Stuart; Alison Yung; Lisa Phillips; Patrick D McGorry Journal: Schizophr Bull Date: 2005-07-14 Impact factor: 9.306
Authors: Thomas P Beresford; Lori Clapp; Brandon Martin; John L Wiberg; Julie Alfers; Henry F Beresford Journal: J Clin Psychopharmacol Date: 2005-08 Impact factor: 3.153
Authors: Joshua A Lile; William W Stoops; Andrea R Vansickel; Paul E A Glaser; Lon R Hays; Craig R Rush Journal: Neuropsychopharmacology Date: 2005-11 Impact factor: 7.853
Authors: Raye Z Litten; Joanne B Fertig; Daniel E Falk; Megan L Ryan; Margaret E Mattson; Joseph F Collins; Cristin Murtaugh; Domenic Ciraulo; Alan I Green; Bankole Johnson; Helen Pettinati; Robert Swift; Maryam Afshar; Mary F Brunette; Nassima A-D Tiouririne; Kyle Kampman; Robert Stout Journal: Alcohol Clin Exp Res Date: 2011-09-26 Impact factor: 3.455
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal Journal: Alcohol Clin Exp Res Date: 2015-02-09 Impact factor: 3.455
Authors: Joseph P Schacht; Konstantin E Voronin; Patrick K Randall; Raymond F Anton Journal: Neuropsychopharmacology Date: 2017-12-06 Impact factor: 7.853
Authors: Hugh Myrick; Xingbao Li; Patrick K Randall; Scott Henderson; Konstantin Voronin; Raymond F Anton Journal: J Clin Psychopharmacol Date: 2010-08 Impact factor: 3.153
Authors: Raymond F Anton; Joseph P Schacht; Konstantin E Voronin; Patrick K Randall Journal: Alcohol Clin Exp Res Date: 2017-06-05 Impact factor: 3.455